• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
PharmaDeals®: Deal Making Spotlight on Pfizer Product Image

PharmaDeals®: Deal Making Spotlight on Pfizer

  • Published: April 2006
  • Region: World
  • 371 Pages
  • PharmaDeals

One of a set of 5 reports detailing the deal making activities of the top 5 pharmaceutical companies, from 2000 up to and including the whole of 2005, if you are looking to partner with big pharma, these reports are crucial to your deal making strategy.

Big pharma companies are often the partner of choice for a smaller pharmaceutical or biotechnology company, not least because of the financially lucrative deals that the larger companies can offer. Indeed, during 2005, seven of the top ten licensing or co-development deals (in terms of total potential value) involved one of the five companies featured in the Spotlight Reports big pharma series. With such financial power, combined with a desire to bolster their development pipeline, big pharma companies are relatively promiscuous in their deal making. These reports will be useful to companies that are looking to collaborate with one of these five companies. By examining equivalent deals in these reports, you will also be able to benchmark your deal with any potential big pharma partner.

A brief historical section puts each company’s current position into perspective and describes some of the significant events that READ MORE >

SPOTLIGHT OVERVIEW 3

SPOTLIGHT FOCUS 5
Pfizer 5
Deal Making Subsidiaries 6

DEAL MAKING 7
Deal Making Overview 7
Financial Information 8
Partnering Companies 9
Interest Areas 9
Licensing Deal Focus 10
R&D Deal Activity 12
Marketing Deal Activity 13

PFIZER DEALS 2000-2005 15

FIELD DEFINITIONS 15
Deal Types 15
Product Types 17
Interest Area 18
Company Types 21

PFIZER DEALS 2000-2005

CATALOGUE 22

CATALOGUE INDEX 342
Index of Partnering Companies 343
Index of Interest Areas 344

APPENDICES 354
Indications and Interest Areas 355
Pfizer articles reprinted from the 360

GUIDE TO PHARMADEALS® AGREEMENTS 371

LIST OF FIGURES
Figure 1 The proportion of the total annual revenues of the top 10 global pharmaceutical companies in 2004 generated by each company
Figure 2 The total number of deals made each year between 2000 and 2005 by Pfizer compared to the average number of deals made by the top 10 global pharmaceutical companies
Figure 3 Deal making activities of Pfizer between 2000 and 2005
Figure 4 Percentage of deals made by Pfizer between 2000 and 2005 involving each deal type
Figure 5 Comparison of the total potential deal values based on deal type
Figure 6 Comparison of deal structure financial components based on deal type
Figure 7 Proportion of partnering companies by size and type
Figure 8 Number of deals involving each therapy interest area
Figure 9 Number of deals involving each technology interest area
Figure 10 In- and out-licensing deals by product area
Figure 11In- and out-licensing deals by phase of product development
Figure 12 Number of licensing deals by therapy interest area
Figure 13 Number of licensing deals by technology interest area
Figure 14 Number of R&D deals by therapy interest area
Figure 15 Number of R&D deals by technology interest area
Figure 16 Proportion of marketing deals by territory
Figure 17 Number of marketing deals by therapy interest area

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos